Literature DB >> 6295780

Characterization of (-)-[3H]dihydroalprenolol binding to intact and broken cell preparations of human peripheral blood lymphocytes.

H Meurs, W van den Bogaard, H F Kauffman, P L Bruynzeel.   

Abstract

In this study we compared characteristics of (-)-[3H]dihydroalprenolol ([3H]DHA) binding sites in crude membrane preparations of human peripheral blood lymphocytes with those of intact, viable cells. A valid determination of specific beta-adrenergic receptor binding in both preparations was obtained by defining non-specific [3H]DHA binding with 10(-6) M l- or dl-propranolol or 10(-3) M l-isoproterenol. Higher concentrations of propranolol were used in prior reports on lymphocyte membranes. We showed that these concentrations may inhibit non-specific binding, causing non-saturability and inhomogeneity of the estimated 'specific' binding. In the intact cell preparations, inclusion of 10(-4) M phentolamine was necessary to reduce the high degree of non-specific binding. By contrast, phentolamine (10(-4) M) showed no effect on the [3H]DHA binding to membrane preparations. At 37 degrees C the [3H]DHA binding to beta-adrenergic receptor sites in both intact and broken cell preparations was rapid and reversible. The sites were stereoselective, as l-propranolol was about two orders of magnitude more potent to inhibit [3H]DHA binding than was the d-isomer. In both preparations, agonists competed for specific binding with a rank order of potency isoproterenol greater than epinephrine greater than norepinephrine, which indicated a beta 2-type of adrenergic receptor. The specific [3H]DHA binding was saturable and Scatchard analysis revealed comparable numbers of homogeneous, non-cooperative binding sites (approximately 1250 receptors/cell in the membrane preparations and 1700 receptors/cell in the intact cells). In spite of these similarities the membrane sites showed a lower affinity for the antagonists [3H]DHA and propranolol than did the intact cell sites, whereas their affinity for the agonists was increased. These differences indicate that the membrane system might be less suited to provide physiologically significant information about the beta-adrenergic receptor system.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6295780     DOI: 10.1016/0014-2999(82)90464-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Brain beta-adrenoceptor binding sites in depressed suicide victims: effects of antidepressant treatment.

Authors:  F De Paermentier; S C Cheetham; M R Crompton; C L Katona; R W Horton
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 2.  Sympathetic modulation of immunity: relevance to disease.

Authors:  Denise L Bellinger; Brooke A Millar; Sam Perez; Jeff Carter; Carlo Wood; Srinivasan ThyagaRajan; Christine Molinaro; Cheri Lubahn; Dianne Lorton
Journal:  Cell Immunol       Date:  2008-03-04       Impact factor: 4.868

Review 3.  Autonomic regulation of T-lymphocytes: Implications in cardiovascular disease.

Authors:  Safwan K Elkhatib; Adam J Case
Journal:  Pharmacol Res       Date:  2019-06-06       Impact factor: 7.658

4.  Plasma catecholamines, beta-adrenergic receptors, and isoproterenol sensitivity in endurance trained and non-endurance trained volunteers.

Authors:  M Lehmann; H H Dickhuth; P Schmid; H Porzig; J Keul
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1984

5.  [Is the alpha adrenergic receptor density increased in intact thrombocytes in non-isometric trained athletes?].

Authors:  M Lehmann; P Schmid; E Bergdolt; E Jakob; U Spöri; J Keul
Journal:  Klin Wochenschr       Date:  1984-10-15

6.  [Beta-adrenergic receptors and plasma catecholamine behavior in trained and untrained athletes].

Authors:  M Lehmann; P Schmid; H Porzig; J Keul
Journal:  Klin Wochenschr       Date:  1983-09-01

Review 7.  Autonomic nervous system and immune system interactions.

Authors:  M J Kenney; C K Ganta
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.